AFP and hepatocellular carcinoma: Interestingly, because an early AFP response has been observed to predict a better treatment outcome in patients who received sorafenib and immune checkpoint inhibitors for advanced HCC,23, 24, 25, 26 we evaluated whether early AFP decline could serve as a favorable surrogate marker for regorafenib, especially for patients with higher baseline AFP levels.